Effects of betamipron on cisplatin nephrotoxicity and its pharmacokinetics in rats.

Abstract

The protective effects of betamipron (BP, N-benzoyl-beta-alanine) on the nephrotoxicity of cisplatin were examined as indicated by body weight gain, ratio of kidney weight to body weight, blood urea nitrogen and serum creatinine levels in tumor-bearing rats. The results showed clearly that administration of BP 1 h after cisplatin treatment affords protection against the nephrotoxicity of cisplatin. Furthermore, the addition of BP to cisplatin had no apparent effect on the efficacy of cisplatin against Walker 256 carcinosarcoma cells in rats. In addition, no observed significant difference in plasma cisplatin concentration between cisplatin with alkaline solution and cisplatin with BP may be partly attributed to the decrease in the cisplatin exsorption to the intestine and its excretion to bile, and to an increase in cisplatin excretion to the urine.

• Authors: J Tokunaga, M Kobayashi, A Kitagawa, C Nakamura, K Arimori, M Nakano
• Journal: Biological & pharmaceutical bulletin (Biol Pharm Bull) Vol. 20 Issue 4 Pg. 386-91 (Apr 1997) ISSN: 0918-6158 [Print] Japan
• PMID: 9145215 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• N-benzoylalanine
• Creatinine
• Alanine
• Cisplatin

Topics

• Alanine (analogs & derivatives, pharmacology)
• Animals
• Antineoplastic Agents (pharmacokinetics, therapeutic use, toxicity)
• Bile (chemistry)
• Blood Urea Nitrogen
• Body Weight (drug effects)
• Carcinoma 256, Walker (drug therapy)
• Cisplatin (pharmacokinetics, therapeutic use, toxicity)
• Creatinine (blood)
• Drug Antagonism
• Intestines (chemistry)
• Kidney (drug effects)
• Male
• Organ Size (drug effects)
• Rats
• Rats, Wistar